Abattis Bioceuticals Corp. (ATTBF)

[Hercules1]

this news out today from ATTBF is simply massive. it got lost in that blood bath today:

1. blood bath in the cannabis sector
2. blood bath in Nasdaq (dropped a DOW equivalent of nearly 500 points
3. blood bath in DOW


anyway check this news from the company again.

I will post it at Camelot also at the Abbatis Royal Hall there. all my friends here are personally invited to Camelot. we can stay in touch there also. we need to keep informing the world about Abbatis Bioceuticals Corporation.

http://www.camelotelitetennis.com/index.php




this is the news I had been waiting for for so long and I had a feeling it was coming.

http://marijuanaindex.org/industry-news-item/


Abattis Announces Completes Agreement With Experion



(via Thenewswire.ca)

Vancouver, BC - April 10th, 2014 - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC PINK: ATTBF) (CSE: ATT), through its wholly owned subsidiary, Northern Vine Canada Inc. ("Northern Vine"), announces that it has entered into a share exchange agreement with Experion Biotechnologies Inc. ("Experion"). Pursuant to the terms of the agreement, Experion and Northern Vine have exchanged 25% of each parties' issued and outstanding common shares. Abattis maintains a 75% ownership in Northern Vine.

Experion is located in Greater Vancouver and is nearing the completion of its Marijuana for Medical Purposes Regulations "MMPR" licence application with Health Canada. Together, Northern Vine and Experion are well positioned to capitalize on the growing trend towards marijuana legalization in the U.S., and medical use in Canada as licensed producers.

Northern Vine, a lab and compounding pharmacy with patented compositions, owns various Natural Health Product licenses for use in the nutraceutical markets. Northern Vine has one remaining outstanding item to complete as required by Health Canada in respect of its controlled substance licence application.

It is anticipated that Experion will provide cannabis for Northern Vine's research and development activities upon receiving its MMPR licence. Experion will also allocate a portion of its 10 acre site for the expansion of Northern Vine's future processing facility and any expansion requirements needed to satisfy cultivation demand in the foreseeable future.

Mike Withrow, President and CEO of Abattis stated: "This is a strategic partnership that links our pending Controlled Substance Licence to another MMPR Application in order to further expand our business potential. This agreement provides the Company with more control of a broader variety of raw materials, for products derived from marijuana, to be processed at our planned botanical drug facility in Quebec. This partnership also creates synergy by joining cultivation with formulation sciences."

About Abattis Bioceuticals Corp.

Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The Company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions, by supplying and partnering with companies to employ its vertical cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: www.abattis.com.

About Experion Biotechnologies Inc.

Experion Biotechnologies Inc. is a team of innovators dedicated to producing, procuring, and providing medical products derived from Cannabis of superior quality in a consistent and timely manner to patients across Canada in accordance with Health Canada regulations. Its current facilities in the Greater Vancouver Area are ready to operate under strict guidelines with standardized operating protocols as a commitment to the quality patients require.

For further information, contact the Company's CEO, Michael Withrow at [phone]

or at [e-mail].